MorphoSys AG (MOR) Q3 2023 Earnings Conference Call November 16, 2023 8:00 AM ET
Company Participants
Julia Neugebauer - Head of IR
Jean-Paul Kress - CEO
Tim Demuth - Chief Research and Development Officer
Lucinda Crabtree - CFO
Conference Call Participants
Derek Archila - Wells Fargo
Xian Deng - UBS
Jason Butler - JMP
James Gordon - JP Morgan
Philippa Pritchard - Morgan Stanley
Manos Mastorakis - Deutsche Bank
Operator
Ladies and gentlemen, thank you for standing by. Welcome, and thank you for joining the Third Quarter Statement 2023 of MorphoSys. Throughout today's recorded call, all participants will be in a listen-only mode. The presentation will be followed by a question-and-answer session. [Operator Instructions]
I would now like to turn the conference over to Julia Neugebauer. Please go ahead.
A - Julia Neugebauer
Ladies and gentlemen, good afternoon or good morning. My name is Julia Neugebauer, Head of Investor Relations at MorphoSys, and it is my pleasure to welcome you to our third quarter 2023 financial and results conference call. With me on the call today are Jean-Paul Kress, our Chief Executive Officer; Tim Demuth, our Chief Research and Development Officer; and Lucy Crabtree, our Chief Financial Officer.
Before we begin, I'd like to remind you on Slide 2, that some of the statements made during the call today are forward-looking statements, including statements regarding our expectations for the commercialization of our products and our development plans and expectations for the compounds in our pipeline, as well as the development plans of our collaboration partners.
These forward-looking statements are subject to a number of risks and uncertainties that may cause our actual results to differ materially, including those described in MorphoSys' 20-F and Annual Report, or for the year ended December 31, 2022, and from time-to-time in other SEC documents of MorphoSys. It is important to
- Read more current MOR analysis and news
- View all earnings call transcripts